Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 5
2016 7
2017 4
2018 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. Vardeny O, et al. Eur J Heart Fail. 2016 Oct;18(10):1228-1234. doi: 10.1002/ejhf.580. Epub 2016 Jun 10. Eur J Heart Fail. 2016. PMID: 27283779 Free PMC article. Clinical Trial.
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Packer M, et al. Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17. Circulation. 2015. PMID: 25403646 Clinical Trial.
Sacubitril/valsartan in PARADIGM-HF - Authors' reply.
Seferovic JP, Claggett B, Solomon SD; PARADIGM-HF investigators. Seferovic JP, et al. Lancet Diabetes Endocrinol. 2017 Jul;5(7):496. doi: 10.1016/S2213-8587(17)30179-1. Lancet Diabetes Endocrinol. 2017. PMID: 28645439 No abstract available.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees. Mogensen UM, et al. Am Heart J. 2017 Jun;188:35-41. doi: 10.1016/j.ahj.2017.02.034. Epub 2017 Mar 14. Am Heart J. 2017. PMID: 28577679 Clinical Trial.
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees. Cannon JA, et al. Eur J Heart Fail. 2017 Jan;19(1):129-137. doi: 10.1002/ejhf.687. Epub 2016 Nov 20. Eur J Heart Fail. 2017. PMID: 27868321 Free PMC article. Clinical Trial.
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Simpson J, et al. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071. doi: 10.1016/j.jacc.2015.08.878. J Am Coll Cardiol. 2015. PMID: 26541915 Free article. Clinical Trial.
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.
Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD; PARADIGM-HF Investigators. Vardeny O, et al. JACC Heart Fail. 2016 Feb;4(2):152-158. doi: 10.1016/j.jchf.2015.10.012. Epub 2015 Dec 30. JACC Heart Fail. 2016. PMID: 26746371 Free article. Clinical Trial.
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees. Mogensen UM, et al. Eur J Heart Fail. 2018 Mar;20(3):514-522. doi: 10.1002/ejhf.1056. Epub 2017 Nov 30. Eur J Heart Fail. 2018. PMID: 29193563 Free PMC article. Clinical Trial.
17 results